Clinical trials: 18-45 Range of Age

Tuberculosis

Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults

• Completed
• Age: 18 to 45 years
• Phase 2
• Vaccines
• Results posted

This observer blind study will assess the safety and immunogenicity of different formulations of GSK Biologicals' 692342 tuberculosis vaccine in healthy adults aged 18 to 45 years with a positive PPD skin test.

Trial name

NCT00621322

Testing

GSK Biologicals' AS01B adjuvant, GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1, GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2

Where

Philippines

Volunteers

180 people, healthy volunteers welcome

Sponsor

GlaxoSmithKline